AI assistant
Sending…
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012
Feb 9, 2012
29864_dirs_2012-02-09_07bdb25d-9487-4c12-a4b2-9c4b81aad421.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-02-08
Reporting Person: SMITH IAN F (EVP & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-02-08 | Common Stock | S | 9667 | $36.80 | Disposed | 24168 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4908 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $36.80 (range $36.48 to $37.20).
F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
More from VERTEX PHARMACEUTICALS INC / MA
Major Shareholding Notification
2026
May 14
Regulatory Filings
2026
May 13
Share Issue/Capital Change
2026
May 13
Share Issue/Capital Change
2026
May 13
Share Issue/Capital Change
2026
May 13
Share Issue/Capital Change
2026
May 13
Share Issue/Capital Change
2026
May 13
Share Issue/Capital Change
2026
May 13
Share Issue/Capital Change
2026
May 13
Declaration of Voting Results & Voting Rights Announcements
2026
May 13